Aggressive medical therapy for the prevention and treatment coronary artery disease

Disease-a-Month

Volumn 44, Issue 1, 1998, Pages 1-40

  Malloy, Mary J ^a   Kane, John P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; ESTROGEN; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; RESIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ANGIOCARDIOGRAPHY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG POTENTIATION; ESTROGEN THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN METABOLISM; PATIENT SELECTION; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; AGE; AGED; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; DECISION MAKING; DRUG COMBINATION; FEMALE; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SEX DIFFERENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; DECISION MAKING; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; SEX FACTORS; TRIGLYCERIDES;

EID: 0031909683     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-5029(98)90000-1     Document Type: Review

References (113)

1. US Dept Health and Human Services. Vital Statistics of the United States, 1988. II: Mortality, Part A. Atlanta Centers for Disease Control and Prevention, 1991.
2. Cupples L, D'Agostino R. Survival following initial cardiovascular events: 30-year follow-up. In: Kannel W, Wolf P, Garrison R, editors. Framingham Heart Study: an epidemiological investigation of cardiovascular disease, Bethesda, National Heart Lung and Blood Institute; 1988. NIH publication No. 88-2969.
3. Cashin-Hemphill J, Mack W, Pogoda M, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990;64:3013-7.
4. Brown B, Albers J Fisher L, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
5. Brown B, Zhao EQ, Sacco D, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
6. Kane J, Malloy M, Ports T, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
7. Watts G, Lewis B, Brunt J, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
8. Buchwald H, Matts J, Ritch L, et al. Effect of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55.
9. Scandinavian Simvastatin Survival Study. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
10. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;338:1301-7.
11. Ross R, Fuster V. The pathogenesis of atherosclerosis. In: Fuster V, Ross R, Topol E, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven: 1996. p. 441-60.
12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993;362:801-9.
13. Hoff H, Bradley W, Heideman C, et al. Characterization of low density lipoprotein-like particles in human aorta from grossly normal and atherosclerotic regions. Biochim Biophys Acta 1979;573:361-74.
14. Phillips N, Waters D, Havel R. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-70.
15. Myers L, Phillips H, Hayel R. Mathematical evaluation of methods for estimation of the concentration of the major lipid components of human serum lipoproteins. J Lab Clin Med 1976;88:491-505.
16. Krauss R, Burke D. Identification of multiple subclasses of plasma low-density lipoproteins in normal humans. J Lipid Res 1982;23:97-104.
17. Chen G, Liu W, Duchateau P, et al. Conformational differences in human apolipoprotein B-100 among subspecies of low-density lipoproteins. J Biol Chem 1994;269:29121-8.
18. McKeone B, Patsch J, Pownall H. Plasma triglycerides determine low-density lipoprotein composition, physical properties, and cell-specific binding in cultured cells. J Clin Invest 1993;91:1926-33.
19. Hiramatsu K, Bierman E, Chait A. Metabolism of low-density lipoprotein from patients with diabetic hypertriglyceridemia by cultured human skin fibroblasts. Diabetes 1985;34:8-14.
20. Walsh M, Galeano N, Arad Y, et al. LDL size but not triglyceride content determines apoprotein B conformation. Circulation 1991;84:II-456;1816.
21. deGraaf J, Hak-Lemmers H, Hectors M, et al. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arteriosclerosis Thromb 1991;11:298-306.
22. Chait A, Brazg R, Tribble D, et al. Susceptibility of small, dense, lowdensity lipoproteins to oxidative modification in subjects. Am J Med 1993;94:350-6.
23. Dejager S, Bruckert E, Chapman M. Dense low-density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993;34:295-308.
24. Rapp J, Lespine A, Hamilson R, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arteriosclerosis Thromb 1994;14:1767-74.
25. Rosengren A, Wilhelmsen L, Eriksson E, et al. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a population sample of middle aged men. BMJ 1990;301:1248-51.
26. Bostom A, Gagnon D, Cupples L, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. Circulation 1994;90:1688-95.
27. Schaefer E, Lamon-Fava S, Jenner J, et al. Lipoprotein(a) levels and risk for coronary heart disease in men: the Lipid Research Clinics Primary Prevention Trial. JAMA 1994;271:999-1003.
28. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction: Results from the prospective Gottingen Risk Incidence and Prevention Study. Eur J Clin Invest 1994;24:444-53.
29. Lawn R, Scanu A: Lipoprotein (a). In: Fuster V, Ross R, Topol E, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. p. 45-359.
30. Kannel W, Neaton J, Wentworth D, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT study. Am Heart J 1986;112:825-6.
31. Gordon D, Knoke L Probstfield J, et al. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 1986;74:1217-25.
32. Gordon T, Castelli W, Hjortland M, et al. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977;62:707-14.
33. Abbott R, Wilson P, Kannel W, et al. High-density lipoprotein cholesterol, total cholesterol screening, and myocardial infazction: the Framingham Study. Arteriosclerosis 1988;8:207-11.
34. Fielding C, Fielding P. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
35. Kunitake S, Mendel C, Hennessy L. Interconversion between apolipoprotein A-I containing lipoproteins of prebeta and alpha electrophoretic mobilities. J Lipid Res 1992;33:1807-16.
36. Kunitake S, La Sala K. Mendel C, et al. Some unique properties of apo A-I-containing lipoproteins with pre-beta electrophoretic mobility: National Institutes of Health Workshop on Lipoprotein Heterogeneity. 1987;87:419-27.
37. Castro G, Fielding C. Early incorporation of cell-derived cholesterol into prebeta-migrating high density lipoprotein. Biochemistry 1988;27:25-9.
38. Parthasarathy S, Barnett J, Fong L. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-83.
39. Klimov A, Nikiforova A, Pleskov V, et al. The protective action of highdensity lipoproteins and lecithin-cholesterol acyltransferase in the peroxide modification of low-density lipoproteins. Biokkimiya 1989;54:118-23.
40. Kunitake S, Jarvis M, Hamilton R, et al. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low-density lipoproteins. Proc Natl Acad Sci USA 1992;89:6993-7.
41. Mackhess M, Arrol S, Abbott C, et al. Is paraoxonase related to atherosclerosis? Chem Biol Interactions 1993;87:161-71.
42. Brown M, Goldstein J. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223-61.
43. Steinberg D, Parthasarathy S, Carew T, et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. Engl J Med 1989;320:915-24.
44. Henriksen T, Mahoney E, Steinberg D. Enhanced macrophage degradation of low-density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low-density lipoproteins. Proc Natl Acad Sci USA 1981;78:6499-503.
45. Parthasarathy S, Frintz D, Boyd D, et al. Macrophage oxidation of low-density lipoprotein generates a form recognized by the scavenger receptor. Arteriosclerosis 1986;6:505-10.
46. Heinecke J. Rosen H, Chait A. Iron and copper promote modification of low-density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984;74:1890-4.
47. Cathcart M, Morel D, Chisolm G. Monocytes and neutrophfis oxidize low-density lipoprotein making it cytotoxic. J Leukocyte Biol 1985;38:341-50.
48. Endmann G, Stanton L, Madden K, et al. CD36 is a receptor of oxidized low-density lipoprotein. J Biol Chem 1993;268:11811-6.
49. Stanton L, White g, Briant C, et al. A macrophage Fc receptor for IgC is also a receptor for oxidized low-density lipoprotein. J Biol Chem 1992;267:22446-51.
50. Kodama T, Freeman M, Rohrer L, et al. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 1990;343:531-5.
51. Rohrer L, Freeman M, Kodama T, et al. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. Nature 1990;343:570-2.
52. Tanner F, Noll G, Boulanger C, et al. Oxidized native low-density lipoproteins inhibit relation of porcine coronary ateries: role scavenger receptor and endothelium-derived nitric oxide. Circulation 1991;83:2012-20.
53. Malloy M, Mietus-Snyder M, O'Connor P, et al. Impaired vasodilatalion in children with genetic dyslipidemias. Circulation 1995;92:I-127.
54. Treasure C, Klein J, Weintraub W, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Eng J Med 1995;8:481-7.
55. Anderson T, Meredith I, Yeung A, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
56. Falk E, Shah P, Fuster V. Pathogenesis of plaque disruption. In: Fuster V, Ross g, Topol E, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. p. 492-507.
57. Fuster V, Badlinen L, Badimon J, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. J Engl Med 1992;326:242-50.
58. Richardson P, Davies M, Born G. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaque. Lancet 1989;2:941-4.
59. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
60. Kannel W. Epidemiologic relationship between the various vascular beds. In: Fuster V, Ross R, Topol E, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. p. 1591-9.
61. Castelli W. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3H-9H.
62. Assman G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 1992;70:10H-13H.
63. Manninch V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyrerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.
64. Austin M, King MC, Vranizan K, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
65. Kannel W, Castelli W, Gordon T, et al. Serum cholesterol, lipoproteins and risk of coronary heart disease. Ann Intern Med 1971;74:1-12.
66. Malloy M, Kane J. Regression of coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia. Can J Cardiol 1993;9:114D-115D.
67. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT). Circulation 1994;89:959-68.
68. Barrett-Connor E, Bush T. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
69. Soma M, Osnago-Gadda I, Raoletti R, et al. The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in post menopausal women. Arch Intern Med 1993;153:1462-8.
70. Byington R, Jukema J, Salonen J, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92:2419-25.
71. Kane J. Structure and function of the plasma lipoproteins and their receptors. In: Fuster J, Ross R, Topol E, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. p. 89-103.
72. Kane J, Malloy M. Disorders of lipoprotein metabolism. In: Greenspan F, Baxter J, editors. Basic and clinical endocrinology. Los Altos (CA): Lange Medical Publications; 1994. p. 649-78.
73. Havel R, Kane J. Structure and metabolism of plasma lipoproteins. In: Scriver C, Beaudet A, Sly W, et al, editors. The metabolic basis inherited disease. New York: McGraw-Hill International Book Co; 1994. p. 1841-51.
74. Keys A, Menotti A, Aravanis C, et al. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med 1984;13:141-54.
75. Kagan A, Harris B, Winkelstein WJ, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: demogrphic physical, dietary and biochemical characteristics. J Chronic Dis 1974;27:345-64.
76. Grundy S. Cholesterol and coronary heart disease: a new era. JAMA 1986;256:2849-58.
77. Grundy S. Lipids, nutrition, and coronary heart disease. In: Fuster V, Ross R, Topol E, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. p. 45-68.
78. Mensink R, Katan M. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med 1990;323:439-45.
79. Vega G, Groszek E, Wolf R, et al. Influence of polyunsaturated fats on composition of plasma lipoproteins and apolipoproteins. J Lipid Res 1982;23:811-22.
80. Shepherd J, Packard C, Patsch J, et al. Effects of dietary polyunsaturated and saturated fat on the properties of high-density lipoprotein and the metabolism of apolipoproteins. J Clin Invest 1978;60:1582-92.
81. Jackson R, Kashyap M, Barnhart R, et al. Influence of polyunsaturated and saturated fats on plasma lipids on lipoproteins in man. Am J Clin Nutr 1984;39:589-97.
82. Reddy B. Amount and type of dietary fat and colon cancer: Animal model studies. Prog Clin Biol Hes 1986;222:295-309.
83. Connor W. Effects of omega-3 fatty acids in hypertriglyceridemic states. Semin Thromb Haemost 1988;14:271-84.
84. Wolfe B, Hayel R, Marliss E, et al. Effects of a three-day fast and of ethanol on splanchnic metabolism of free fatty acids, amino acids and carbohydrates in healthy young men. J Clin Invest 1976;57:329-40.
85. Bradford R, Shear C, Chremos A, et al. Extended clinical evaluation of lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
86. Kane J, Malloy M, Tun P, et al. Normalization of levels of low-density lipoproteins in serum of patients with heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 1981;304:251-8.
87. Shepherd J, Packard C, Patsch J, et al. Effects of nicotinic acid therapy on plasma high-density lipoprotein subsfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979;63:858-67.
88. Knopp R. Niacin and hepatic failure. Ann Intern Med 1991;111:769.
89. Malloy M, Kane J, Kunitake S, et al. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med 1987;107:616-23.
90. Grundy S, Vega G, Bilheimer D. Influence of combined therapy with mevinolin and interruption of bile acid-reabsorption on low-density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med 1985 103:339-43.
91. Illingworth D. Mevinolin plus colestipol in therapy for heterozygous familial hypercholesterolemia. Ann Intern Med 1984;101:598-604.
92. Armstrong M, Megan M. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res 1972:30:675-80.
93. Glagov S, Weisenbert E, Zarins C, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-5.
94. Taeymans Y, Theroux P, Lesperance J, et al. Quantitative angiographic morphology of the coronary artery lesions at risk of thrombotic occlusion. Circulation 1985;1:78-85.
95. Little W, Constantinescu G, Applegate R, et al. Can coronary angiography predict the site of subsequent myocardial infarction in patients with mild to moderate coronary artery disease? Circulation 1988;78:1157-66.
96. Haskell W, Alderman E, Fair J, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.
97. Sacks F, Pasternak R, Gibson C, et al. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet 1994;344:1182-6.
98. MRFIT. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982;245:1465-77.
99. Blankenhorn D, Azen S, Kramsch D, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:967-76.
100. Pitt B, Mancini G, Ellis S, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995;26:1133-9.
101. MAAS. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
102. Jukema J, Bruschke A, van Boven A, et al. Effects of lipid lowering by pravastatin in progression and regression of coronary artery disease in symptomatic men with moderately elevated serum cholesterol levels: the Regress Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
103. Brown B, Zhao XQ, Sacco D, et al. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu Rev Med 1993;44:365-76.
104. Brown W, Impact of management in stabilization and regression of coronary disease. In: Fuster V, Ross R, Topol E, editors. Artherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. p. 191-205.
105. Canner P, Berge K, Wenget N, et al. Coronary drug project research group: fifteen years mortality in coronary drug project patients: term benefit with niacin. J Am Coll Cardiol 1986;8:124555.
106. Hulley S, Walsh L Newman T. Health policy on cholesterol: time to change directions. Circulation 1992;86:1027-9.
107. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference Low Blood Cholesterol: mortality associations. Circulation 1992;86:1046-60.
108. Stamler J, Stamler R, Brown W, et al. Serum cholesterol: doing the right thing. Circulation 1993;88:1956-60.
109. Law M, Thompson S, Wald N. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308:373-9.
110. Neaton M, Blackburn H, Jacobs D, et al. Serum cholesterol level mortality findings for men screened in the multiple risk factor intervention trial. Arch J Med 1992;152:1490-1500.
111. Iso H, Jacobs D, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,922 men screened for the Multiple Risk Factor Zntervention Trial. N Engl J Med 1989;320:904-10.
112. Yano K, Reed D, Madean C. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989;20:1460-5.
113. Newman T, Hulley S. Carcinogenicity of lipid-powering drugs. JAMA 1996;275:55-60.